6 results match your criteria: "National Reference Center of HIV[Affiliation]"
Performance evaluation of the new Access HIV Ag/Ab combo assay on the DxI 9000 Access Immunoassay Analyzer.
J Clin Virol
October 2024
CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France; Univ Rouen Normandie, Univ de Caen, INSERM, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France. Electronic address:
Fourth-generation HIV immunoassays have been developed to reduce the window period of detection during seroconversion period, allowing for the detection of early and established infections. The aim of this work was to evaluate a newly developed assay, Access HIV Ag/Ab combo on the novel high throughput DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
View Article and Find Full Text PDFBackground: A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. However, no clinical data are available regarding critically-ill JN.
View Article and Find Full Text PDFEvaluation of the ELITechGroup solution for plasma HIV-1 RNA quantification.
J Clin Virol
August 2024
Univ Rouen Normandie, Univ de Caen, INSERM, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France. Electronic address:
Article Synopsis
- Many manufacturers have created new kits for quantifying plasma HIV-1 RNA, and a recent kit combining the ELITe InGenius® instrument with the HIV1 ELITe MGB® kit has been launched globally.
- The study aimed to compare the clinical performance of this new kit with Hologic's Aptima® HIV-1 Quant Dx kit using a variety of HIV-1 samples to assess linearity, specificity, and sensitivity.
- Results showed that the two kits had an overall agreement of 83.7%, with slight differences in detection rates, but both were effective for monitoring viral load in patients with different HIV-1 strains.
First evidence of a mother-to-child transmission of an HIV-1/MO intergroup recombinant form.
Clin Microbiol Infect
May 2024
Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France.
In vitro replicative potential of an HIV-1/MO intergroup recombinant virus compared to HIV-1/M and HIV-1/O parental viruses.
Sci Rep
January 2024
Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, 76000, Rouen, France.
Article Synopsis
- Genetic recombination is a key process in the evolution of HIV-1, allowing groups M and O to create unique hybrid forms known as HIV-1/MO intergroup recombinants.
- A study focused on the replicative potential of these recombinant forms, particularly looking at a specific recombination pattern between groups M and O and analyzing their viral activity in the lab.
- The findings indicated that while the group M parental virus showed more viral activity than group O, the recombinant virus displayed a mix of both parent characteristics, suggesting a complex interplay in its ability to replicate and evolve.
HIV-1 Non-Group M Strains and ART.
Viruses
March 2023
Univ Rouen Normandie, UNICAEN, INSERM, DYNAMICURE UMR 1311, and CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France.
To eliminate HIV infection, there are several elements to take into account to limit transmission and break viral replication, such as epidemiological, preventive or therapeutic management. The UNAIDS goals of screening, treatment and efficacy should allow for this elimination if properly followed. For some infections, the difficulty is linked to the strong genetic divergence of the viruses, which can impact the virological and therapeutic management of patients.
View Article and Find Full Text PDF